AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript

AtriCure (NASDAQ: ATRC ) reported second-quarter financial results on Thursday.

The transcript from the company's second-quarter earnings call has been provided below.

This transcript is brought to you APIs.

For real-time access to our entire catalog, please visit for a consultation.

The full earnings call is available at Summary AtriCure Inc reported Q2 2026 worldwide revenue of $154 million, a 13% increase, with U.S. revenue up 14%, driven by key product adoption across various franchises.

The company highlighted strategic initiatives such as the BOX No AF clinical study and LEAPS trial, which are progressing well and expected to be significant market catalysts.

AtriCure reported $27 million in adjusted EBITDA and $9 million in net income, reflecting strong profitability and financial position, with a positive outlook for 2026 revenue of $602-610 million.

The pain management franchise showed robust growth, particularly through CryoSphere Max and recent product launches like CryoXT, supporting future revenue contributions.

Management emphasized the competitive advantage of AtriCure's innovation, clinical trials, and educational efforts in maintaining market leadership, with plans for continued investment in these areas.

Full Transcript OPERATOR Good afternoon and welcome to AtriCure's second quarter 2026 earnings conference call.

This call is being recorded for replay purposes and at this time all participants are in a listen-only mode.

We will be facilitating a question-and-answer session following prepared remarks from AtriCure's management.

I would now like to turn the call over to Marissa Beitzsche from the Gilman Group for a few introductory comments.

You may begin.

Marissa Beitzsche, The Gilman Group (Investor Relations) Thank you.

By now you should have received a copy of the earnings press release.

If you have not received a copy, please call 513-644-4484 to have one emailed to you.

Before we begin today, let me remind you that the Company's remarks include forward-looking statements.

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control, including risks and uncertainties described from time to time in AtriCure's SEC filings.

These statements include, but are not limited to, financial expectations and guidance, expectations regarding the potential market opportunity for AtriCure's franchises and growth initiatives, future product approvals and clearances, competition, reimbursement, and clinical trial enrollment and outcomes.

AtriCure's results may differ materially from those projected.

AtriCure undertakes no obligation to publicly update any forward-looking statements.

Additionally, we refer to non-GAAP financial measures, specifically constant currency revenue growth, adjusted EBITDA and adjusted earnings or loss per share.

A reconciliation of these non-GAAP financial measures with the most directly comparable GAAP measures is included in our press release which is available on our website.

And with that I would like to turn the call over to Mike Carroll, President and CEO.

Mike Carroll, President and CEO Thank you, Marissa, and good afternoon everyone.

Thank you for joining us on today's call.

AtriCure delivered solid second quarter results with worldwide revenue of $154 million and growth of 13%.

Our U.S. business led the growth with an increase of 14% year over year, fueled by continued adoption of CryoSphere Max and CryoXT probes in our pain management franchise, AtriClip Flex Mini and Pro Mini devices in our appendage management franchise, and the Encompass Clamp in our open ablation franchise.

We also generated over $27 million of adjusted EBITDA and $9 million of net income, further reinforcing the outstanding progress we are making to improve profitability and demonstrate the overall strength of our business as we enter the back half of the year.

The breadth of our platform gives me tremendous confidence and I'm energized by what our team can accomplish as we advance our key strategic initiatives.

To that point, I would like to take a moment to highlight one of these strategic initiatives: the BOX No AF clinical study, the benefits of ablation and LAA management in cardiac surgery procedures for patients without a history of atrial fibrillation.

We started enrolling this trial in the fourth quarter of last year and have now surpassed the 50% enrollment mark.

With over 500 patients in the trial, we remain on track to complete full enrollment of 960 total patients by the end of this year, well ahead of our original plan.

We believe the speed of enrollment and site engagement reflect the strong interest and value that cardiac surgeons place on managing the most common complication of cardiac surgery and the sheer size of the market opportunity.

Postoperative AFib places a significant burden on their patients and the need goes beyond patient care.